{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:16:20Z","timestamp":1793333780411,"version":"4.5.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Therapeutic drug monitoring on the basis of mycophenolic acid (MPA) trough levels is associated with higher effectiveness of mycophenolate mofetil in maintaining remission in children with steroid-dependent nephrotic syndrome\/frequently relapsing nephrotic syndrome.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Dose adjustments on the basis of MPA trough levels personalize treatment, are associated with higher effectiveness, and help minimize potential toxicity.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Maintaining MPA trough levels above 2.9\n                            <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                            g\/ml provides a relapse-free survival rate more than 85%, similar to that of more toxic drugs.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The effectiveness of therapeutic drug monitoring (TDM) of mycophenolic acid (MPA) trough levels in children with steroid-dependent nephrotic syndrome (SDNS)\/frequently relapsing nephrotic syndrome (FRNS) treated with mycophenolate mofetil (MMF) has not been adequately assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed an international, retrospective study including children with SDNS\/FRNS treated with MMF as the first-line steroid-sparing agent and a follow-up of more than 6 months. Patients were categorized into two groups: TDM, if MPA trough levels were monitored, and no-TDM, if not. In the TDM group, MMF doses were adjusted to maintain MPA trough levels of more than 3\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      g\/ml, unless toxicity occurred. The primary outcome was relapse-free survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 167 patients were observed, 90 in the TDM group and 77 in the no-TDM group. Relapse-free survival over the total follow-up was significantly longer in the TDM group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001, log-rank test) with an estimated relapse-free survival at 6 months of 73% for the TDM group and 55% for the no-TDM group. After correcting for potential confounders, the association remained statistically significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). TDM patients also received lower doses of prednisone after MMF introduction. In the TDM group, children were more likely to modify their initial dose (90% versus 9%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Although MMF dose was not associated with relapse (median 1186 versus 1298 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.14), MPA trough levels were significantly higher in children who did not relapse (4.0 versus 2.7\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      g\/ml,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). Among children maintaining mean MPA levels more than 2.9\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      g\/ml, relapse-free survival at 6 months was 86%. Reported side effects were similar in both groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Monitoring MPA trough levels was associated with an approximately 20% higher MMF effectiveness in maintaining remission at 6 months in children with SDNS\/FRNS. Personalized MMF dosing, adjusted to maintain MPA levels more than 2.9\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      g\/ml, was both safe and effective. We recommend including MPA trough level monitoring in future studies comparing MMF with other steroid-sparing agents in children with SDNS\/FRNS.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.0000000824","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:00:28Z","timestamp":1758038428000},"page":"1744-1752","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness of Mycophenolate Mofetil Trough Level Monitoring in Children with Relapsing Nephrotic Syndrome"],"prefix":"10.2215","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4833-4128","authenticated-orcid":false,"given":"William","family":"Morello","sequence":"first","affiliation":[{"name":"Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bernardi","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, Reference Center for Idiopathic Nephrotic Syndrome in Children and Adults, University Hospital Necker-Enfants Malades, Assistance Publique - H\u00f4pitaux de Paris (APHP), Imagine Institute, INSERM U1163, Paris Cit\u00e9 University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Puccio","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4642-1304","authenticated-orcid":false,"given":"Anita Sofia","family":"Bellotti","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7130-0439","authenticated-orcid":false,"given":"Evgenia","family":"Preka","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, Reference Center for Idiopathic Nephrotic Syndrome in Children and Adults, University Hospital Necker-Enfants Malades, Assistance Publique - H\u00f4pitaux de Paris (APHP), Imagine Institute, INSERM U1163, Paris Cit\u00e9 University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Grapin","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, Reference Center for Idiopathic Nephrotic Syndrome in Children and Adults, University Hospital Necker-Enfants Malades, Assistance Publique - H\u00f4pitaux de Paris (APHP), Imagine Institute, INSERM U1163, Paris Cit\u00e9 University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3260-0709","authenticated-orcid":false,"given":"Maud","family":"Pr\u00e9vot","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, Reference Center for Idiopathic Nephrotic Syndrome in Children and Adults, University Hospital Necker-Enfants Malades, Assistance Publique - H\u00f4pitaux de Paris (APHP), Imagine Institute, INSERM U1163, Paris Cit\u00e9 University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Charbit","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, Reference Center for Idiopathic Nephrotic Syndrome in Children and Adults, University Hospital Necker-Enfants Malades, Assistance Publique - H\u00f4pitaux de Paris (APHP), Imagine Institute, INSERM U1163, Paris Cit\u00e9 University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Nittoli","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2011-2160","authenticated-orcid":false,"given":"Maurizio","family":"Gallieni","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Ghio","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Edefonti","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-1359","authenticated-orcid":false,"given":"Olivia","family":"Boyer","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, Reference Center for Idiopathic Nephrotic Syndrome in Children and Adults, University Hospital Necker-Enfants Malades, Assistance Publique - H\u00f4pitaux de Paris (APHP), Imagine Institute, INSERM U1163, Paris Cit\u00e9 University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-4475","authenticated-orcid":false,"given":"Giovanni","family":"Montini","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023-2027, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"issue":"10404","key":"B1-20251219","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0140-6736(23)01051-6","article-title":"Childhood nephrotic syndrome","volume":"402","author":"Vivarelli","year":"2023","journal-title":"Lancet."},{"issue":"12","key":"B2-20251219","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1007\/s00467-018-3970-y","article-title":"Mycophenolate mofetil for sustained remission in nephrotic syndrome","volume":"33","author":"Querfeld","year":"2018","journal-title":"Pediatr Nephrol."},{"issue":"3","key":"B3-20251219","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","article-title":"IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome","volume":"38","author":"Trautmann","year":"2023","journal-title":"Pediatr Nephrol."},{"issue":"10","key":"B4-20251219","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1681\/ASN.2012121200","article-title":"Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome","volume":"24","author":"Gellermann","year":"2013","journal-title":"J Am Soc Nephrol."},{"issue":"10","key":"B5-20251219","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2215\/CJN.00320116","article-title":"Mycophenolic acid pharmacokinetics and relapse in children with steroid-dependent idiopathic nephrotic syndrome","volume":"11","author":"Tellier","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"key":"B6-20251219","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jbi.2018.02.019","article-title":"A clinician friendly data warehouse oriented toward narrative reports: Dr. Warehouse","volume":"80","author":"Garcelon","year":"2018","journal-title":"J Biomed Inform."},{"issue":"2","key":"B7-20251219","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1681\/ASN.2021050643","article-title":"Mycophenolate mofetil after rituximab for childhood-onset complicated frequently-relapsing or steroid-dependent nephrotic syndrome","volume":"33","author":"Iijima","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B8-20251219","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12882-024-03739-z","article-title":"Efficacy and safety of oral cyclophosphamide versus mycophenolate mofetil in childhood nephrotic syndrome: an open-label comparative study","volume":"25","author":"Dhooria","year":"2024","journal-title":"BMC Nephrol."},{"issue":"6","key":"B9-20251219","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/FTD.0000000000000671","article-title":"Generation and validation of a limited sampling strategy to monitor mycophenolic acid exposure in children with nephrotic syndrome","volume":"41","author":"Benz","year":"2019","journal-title":"Ther Drug Monit."},{"key":"B10-20251219","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejps.2015.06.017","article-title":"Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters","volume":"77","author":"Sobiak","year":"2015","journal-title":"Eur J Pharm Sci."},{"issue":"2","key":"B11-20251219","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00467-021-04983-3","article-title":"Update on the treatment of steroid-sensitive nephrotic syndrome","volume":"37","author":"Zotta","year":"2022","journal-title":"Pediatr Nephrol."},{"issue":"11","key":"B12-20251219","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1093\/ndt\/gfn360","article-title":"Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil","volume":"23","author":"Neumann","year":"2008","journal-title":"Nephrol Dial Transplant."},{"issue":"10","key":"B13-20251219","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.2215\/CJN.00380116","article-title":"Ethnic differences in incidence and outcomes of childhood nephrotic syndrome","volume":"11","author":"Banh","year":"2016","journal-title":"Clin J Am Soc Nephrol."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:58Z","timestamp":1786369378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000000824","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"assertion":[{"value":"2025-04-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}